Debanjan Ray, Synthekine CEO
Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks
Synthekine reeled in a $100 million financing to bankroll its IL-2 ambitions and get into the clinic with its first CAR-T.
The Series C fundraise will beef up the Merck-partnered biotech’s shot at proving itself in a field that ran into major setbacks last year, when Sanofi took a $1.6 billion hit to its IL-2 work, and Bristol Myers Squibb and collaborator Nektar Therapeutics wound down programs from their $3.6 billion pact.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
